SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing heightened community debate as traders split between those viewing recent price action as a technical breakout opportunity and long-term skeptics who remain wary of its historical performance and lack of confirmed high-profile partnerships. The conversation is driven by a mix of market-wide altcoin momentum, renewed interest in Japan-based blockchain narratives, and speculative anticipation regarding the project's evolving ecosystem.

TOSHI

TOSHI is seeing a surge in community engagement as investors speculate on potential exchange listings and its role as a key asset within the Base network ecosystem. Enthusiasts are actively accumulating tokens, citing favorable chart patterns and historical performance as reasons for their growing optimism.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific (APAC). Its brands include Abercrombie and Hollister. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch ($ANF) is experiencing intense market volatility as investors weigh robust earnings beats and aggressive share buyback programs against concerns regarding tariff-related headwinds and cautious guidance. The stock remains a focal point for community discussion, with traders closely debating its low P/E valuation, the potential for short squeezes, and the company's ability to maintain momentum amidst a shifting retail landscape.

Spitcoin is a community-driven cryptocurrency built on the Solana blockchain that powers a decentralized creator economy through the LimitlessFlo platform.  The project focuses on giving creators full control over their content and earnings by enabling instant monetization from day one—through tips, subscriptions, live streaming, and marketplace transactions—without the restrictions of traditional platforms like bans, algorithm suppression, or delayed payouts.  At its core, Spitcoin is about combining meme culture with real utility, creating a self-sustaining ecosystem where platform activity drives token demand, and token usage fuels platform growth.

SpitCoin

SpitCoin is gaining momentum as the community highlights its utility as the powering technology behind the Limitlessflo platform. Investors are actively discussing the token alongside WAGMI, viewing both as emerging projects with significant growth potential.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is experiencing significant market volatility and active investor debate as it approaches its earnings report, with sentiment split between those bullish on the company's long-term expansion into AI and logistics and those concerned about consumer spending habits and high valuations. The community is heavily focused on the stock's recent price swings and whether the platform can maintain its growth narrative amidst stiff competition and broader economic pressures.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad is seeing renewed market attention and high social media engagement as investors highlight its cultural persistence and long-term community dedication. The community is buzzing over its recent expansion into consumer health products, fueling active discussions about its potential for long-term growth as a major memecoin contender.

Hormuz Toll Fund (HTF) is a community-driven SPL token deployed on the Solana blockchain. The project takes its name and visual identity from the Strait of Hormuz, the maritime corridor through which a significant share of global seaborne crude oil transits, and adopts an energy and shipping-toll motif as the basis for its branding and community culture. Despite the word "Fund" in its name, HTF is not an investment fund, security, or pooled investment vehicle, and the project holds no physical commodity, oil contracts, or shipping rights of any kind. It is not affiliated with any government, maritime authority, or shipping entity. The token follows the standard Solana SPL fungible token model and trades on Solana-native decentralized exchanges with all transfers and balances publicly verifiable on-chain.

Hormuz Toll Fund

Hormuz Toll Fund is gaining traction as traders speculate on the project's long-term utility and potential for higher time frame growth.

LCX.com is a platform that innovates capital markets by providing solutions for compliant digital assets and security tokens. It is a secure and compliant platform for buying, selling, transferring, and storing digital currency.

LCX is generating significant community discourse as investors debate its long-term potential versus concerns over regulatory hurdles, exchange performance, and perceived lack of transparency. While some users are aggressively accumulating during price pullbacks and highlighting upcoming catalysts like MiCA approvals and RWA initiatives, others remain skeptical about the project's viability and market sentiment.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is attracting significant attention as investors monitor its lead drug candidate, ivonescimab, which is undergoing an FDA BLA review with a decision expected later this year. The community remains highly focused on the company's clinical pipeline and upcoming ASCO presentation, with many viewing the stock's recent volatility as a consolidation phase before potentially impactful regulatory and trial milestones.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos is experiencing heavy bearish sentiment and community frustration, with many users labeling it a "pump and dump" and questioning its long-term viability given its significant year-to-date losses. While some investors remain focused on the 15% APY staking rewards as a potential long-term play, the broader community discourse is dominated by disappointment over the token's inability to decouple from Bitcoin's volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Healthcare Disruption, AI Biologics, and Wall Street Upgrades Ignite a Midday Market Surge

Healthcare innovators are pushing the markets today. $TGNT, $AGL, $ATRA, $ASBP

<ul class="summary-bullets"><li>Aspire Biopharma is expanding beyond its core biotech business and recently announced a $30 million all-cash acquisition of Dura Control Systems, a global automotive supplier.</li><li>The firm secured a $22.5 million credit facility for the acquisition and added that it does not expect to raise additional equity.</li><li>Aspire Biopharma had implemented a 1-for-40 reverse stock split on Jan. 16, 2026.</li></ul>Shares of Aspire Biopharma Holdings (ASBP) surged more than 21% on Monday, logging their biggest jump in over a month as a fresh $5 million buyback plan sparked renewed investor interest.Aprire Biopharma’s board approved a share repurchase program of up to $5 million, to be funded from existing cash and executed over time through open-market purchases or private transactions.“Aspire’s strengthened financial position provides us with significant flexibility in executing our capital allocation strategy. The Board's authorization of a $5 million share repurchase program further supports our commitment to returning value to shareholders,” said CEO Kraig Higginson.<h2 class="st-heading-2">Move Beyond Biotech</h2>Aspire Biopharma is expanding beyond its core biotech business with a <a href="https://stocktwits.com/news-articles/markets/equity/why-asbp-stock-is-surging-after-78-percent-crash/cZBIWpURICk">planned</a> $30 million all-cash acquisition of Dura Control Systems (DCS), a global automotive supplier. DCS generates over $200 million in annual revenue and more than $20 million in earnings, with a broad portfolio of parts and patents used by major automakers.To support the acquisition, it recently secured a $22.5 million credit facility and added that it does not expect to raise additional equity.Separately, Aspire is growing its consumer segment through its Buzz Bomb unit, which recently partnered with Interwest Brokerage to expand retail distribution. The product is a sublingual caffeine powder that delivers a quick energy boost without the need for traditional drinks like coffee or energy beverages.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/ASBP">ASBP</a> remained ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.One user said every dip was a buying opportunity as the stock climbs toward $2. It is currently trading around $0.3.<stembedurl>https://stocktwits.com/JOHNNY_DANGER/message/651520470</stembedurl>However, another user said the $5 million buyback looks more like a “distraction” than a “deal.”<stembedurl>https://stocktwits.com/Observenact/message/651516573</stembedurl>Aspire Biopharma implemented a 1-for-40 reverse stock split on Jan. 16, 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/poet-stock-biggest-intraday-fall-marvell-order-cancelled/cZBNt3nRePh">POET Stock On Track To Record Biggest Single-Day Fall After Disclosing Order Cancellation From Celestial AI – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

ASBP Stock Jumps 21% On Buyback Offer – Retail Believes Every Dip’s A Buying Opportunity

Aspire Biopharma’s board approved a share repurchase program of up to $5 million, which will be funded from existing cash.

Equity

<ul class="summary-bullets"><li>Aspire Biopharma also secured a commitment for a $22.5 million credit facility to help fund its planned acquisition of Dura Control Systems.</li><li>The deal is not expected to require any additional equity raise, the company said.</li><li>Aspire’s unit, Buzz Bomb Caffeine Company, recently partnered with Interwest Brokerage to expand its retail presence in the Intermountain West.</li></ul>Aspire Biopharma Holdings (ASBP) grabbed retail traders’ attention Tuesday after its shares surged more than 20% in pre-market trading, following the successful close of a $21 million private placement that lifted its shareholders’ equity above Nasdaq’s minimum listing requirement.<a href="https://stocktwits.com/symbol/ASBP">ASBP shares</a> are poised to bounce back after four straight sessions of losses that saw it plunge more than 78% and fall to a 52-week low on Monday.The company also secured a commitment for a $22.5 million credit facility to help fund its planned acquisition of Dura Control Systems (DCS). The deal is not expected to require any additional equity raise, Aspire Biopharma added.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier. Message volumes on the platform surged 1,175% over a 24-hour period and a whopping 5,000% over a seven-day period.One user expects the stock to reclaim $1. It last traded above that on April 14.<stembedurl>https://stocktwits.com/Kittu20/message/650857092</stembedurl>Another user expects range-bound trading.<stembedurl>https://stocktwits.com/momirk/message/650856886</stembedurl><h2 class="st-heading-2">Beyond Drug Delivery</h2>Last week, Aspire Biopharma signed a letter of intent to acquire DCS in an all-cash deal valued at $30 million. DCS is a global automotive supplier with over $200 million in FY2025 revenue and more than $20 million in earnings before interest, tax, depreciation, and amortization (EBITDA).DCS holds a broad portfolio of parts and patents serving major automakers. Aspire said the acquisition would help it evolve into a diversified, high-revenue business beyond its core drug delivery technology.Prior to that, Aspire’s unit, Buzz Bomb Caffeine Company, partnered with Interwest Brokerage to expand its retail presence in the Intermountain West. The unit’s Buzz Bomb is a single-serve caffeine powder taken under the tongue that delivers 50 mg of caffeine, eliminating the need for drinks like coffee or energy beverages.Year-to-date, the stock has slumped more than 93%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. INTC and AMD hit fresh records on Thursday. (Image source: Getty Images)

ASBP Bulls Back In Control After 78% Crash: What Changed? 

The company closed a $21 million private placement that lifted its shareholders’ equity above Nasdaq’s minimum listing requirement.

ASBP Stock Back On Retail Radar After 78% Crash – Bulls Eye $1 Comeback

<ul class="summary-bullets"><li>Lucid fell more than 7.5% on Monday, extending a five-day decline to a 52-week low of $6.75 after recent financing announcements and the appointment of a new CEO.</li><li>Aspire Biopharma declined to a low of $0.22 after announcing an additional $22.5 million credit line to fund an acquisition.</li><li>Wearable Devices fell to a low of $1.10 after the company entered a warrant inducement agreement for $5 million.</li></ul>Lucid Group Inc. (LCID), Aspire Biopharma Holdings Inc. (ASBP) and Wearable Devices Ltd. (WLDS) stocks slipped to fresh intraday lows on Monday, with all three companies recording new 52-week lows.The declines came amid leadership uncertainty, financing concerns, and downward revisions to price targets from Wall Street analysts, which weighed on investor sentiment.<h2 class="st-heading-2">Lucid Drops On Financing, Leadership Concerns</h2>Shares of electric car manufacturer Lucid fell more than 7.5% on Monday, extending a five-day decline, as it fell to a 52-week low of $6.75. The drop followed recent financing decisions and the appointment of a new CEO.Last week, Lucid announced a $1.05 billion capital raise, including a pricing of its $300 million registered offering of common stock. The company also appointed Silvio Napoli as the new CEO.However, the company’s shares edged up after the market closed on Monday following Uber Technologies (UBER) saying it had <a href="https://stocktwits.com/news-articles/markets/equity/lcid-stock-pops-after-hours-as-uber-loads-up-on-more-shares/cZB46cLRIzu">raised its stake</a> in the EV company to 11.5%.Amid these announcements, the stock also garnered attention from Wall Street analysts, with TD Cowen and Baird lowering price targets on the company. TD Cowen cut Lucid’s price target to $10 from $19 and kept a ‘Hold’ rating on the shares, while Baird lowered the price target on Lucid to $12 from $14 and maintained a ‘Neutral’ rating on the shares.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LCID">LCID stock</a> remained in the ‘extremely bullish’ territory at the time of writing, amid ‘extremely high’ message volumes. LCID shares have declined more than 39% this year.<figure class="image"><img src="https://news.stocktwits-cdn.com/Lucid_png_3d11f9354f.webp" alt="Lucid.png" width="1280" height="156"></figure><h2 class="st-heading-2">Aspire Biopharma Slips On Financing Concerns</h2>ASBP stock declined for four straight days, slipping to a low of $0.22 on Monday after it announced it had closed the final tranche of a $21 million private placement and secured an additional $22.5 million credit line to fund the acquisition of Dura Control Systems.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ASBP">ASBP stock</a> improved from ‘bullish’ to the ‘extremely bullish’ territory over the past day, amid ‘extremely high’ message volumes. ASBP shares have declined more than 95% this year.<figure class="image"><img src="https://news.stocktwits-cdn.com/Aspire_png_0d0bf386ff.webp" alt="Aspire.png" width="1263" height="157"></figure><h2 class="st-heading-2">WLDS Falls On Warrant Inducement</h2>Shares of Wearable Devices Ltd. (WLDS) fell to a low of $1.10 on Monday after the company entered a warrant inducement agreement for $5 million that it said it would use for working capital requirements and other general corporate purposes.The company also <a href="https://stocktwits.com/news-articles/markets/equity/why-is-wlds-stock-soaring-today-best-gains-in-7-months/cZBdKfQRIz0">announced a collaboration</a> with Meta-Bounds Inc. to develop intuitive neural control for augmented reality glasses, although it failed to address investor concerns about dilution and funding needs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WLDS">WLDS stock</a> improved from ‘neutral’ to the ‘extremely bullish’ territory over the past day, amid ‘extremely high’ message volumes. WLDS shares have declined more than 65% this year.<figure class="image"><img src="https://news.stocktwits-cdn.com/WLDS_png_b4049d50bf.webp" alt="WLDS.png" width="1264" height="154"></figure>&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

LCID, ASBP, WLDS Stocks Hit 52-Week Lows: What Drove The Selloff?

Lucid Group Inc. (LCID), Aspire Biopharma Holdings Inc. (ASBP) and Wearable Devices Ltd. (WLDS) stocks slipped to fresh intraday lows on Monday, with all three companies recording new 52-week lows.

The declines came amid leadership uncertainty, financing concerns, and downward revisions in price targets from Wall Street analysts.

<ul class="summary-bullets"><li>LCID slid for a third straight day after TD Cowen and Baird trimmed their price targets following recent company updates and capital raises.</li><li>ABT dropped after cutting its 2026 EPS outlook to $5.38-$5.58 due to the impact of its $23 billion acquisition of Exact Sciences.</li><li>ASBP slumped after shareholders approved a reverse stock split and authorized additional equity issuance tied to preferred-stock conversion and financing deals.</li></ul>Shares of Lucid Group (LCID), Abbott Laboratories (ABT) and Aspire Biopharma Holdings (ASBP) dropped to fresh 52-week lows Thursday, bucking a broader market rally, as investors weighed softer growth prospects and dilution risks across the three companies.On Thursday,&nbsp;<a href="https://stocktwits.com/symbol/LCID">LCID</a> and&nbsp;<a href="https://stocktwits.com/symbol/ABT">ABT</a> shares each fell about 6%, while&nbsp;<a href="https://stocktwits.com/symbol/ASBP">ASBP</a> slumped 45%.<h2 class="st-heading-2">LCID Falls As Outlook Confidence Wavers</h2>LCID shares fell 6% on Thursday, extending their decline to a third straight session, after multiple Wall Street firms lowered price targets following recent company updates in a weaker auto market.&nbsp;Earlier this week, TD Cowen analyst Itay Michaeli cut the firm’s price target to $10 from $19 and maintained a ‘Hold’ rating, saying automakers appear better positioned than suppliers in the first quarter (Q1) to provide investors with outlook “reassurances and retaining guidance credibility.” The brokerage added that guide-down risk across the sector remains low.Baird also lowered its price target to $12 from $14 and kept a ‘Neutral’ rating after updating its model following the appointment of a permanent CEO and expansion of Lucid’s partnership with Uber.Investor sentiment has also remained under pressure from a recent $1.05 billion capital raise and a $300 million stock offering. The company is targeting production of 25,000 to 27,000 vehicles in 2026, but produced 5,500 vehicles and delivered 3,093 units in Q1 after deliveries were temporarily affected by a Gravity SUV seat-belt recall.<h2 class="st-heading-2">ABT Slides On Exact Sciences Impact To Bottomline</h2>ABT shares posted their worst session in nearly three months on Thursday after the company lowered its 2026 adjusted profit outlook due to the impact of its $23 billion acquisition of Exact Sciences.Abbott cut its full-year outlook and now expects adjusted earnings per share of $5.38 to $5.58, down from its earlier forecast of $5.55 to $5.8. Investors focused on softer organic growth trends, weakness in the nutrition segment and slower-than-expected momentum in diabetes and structural-heart devices, facing competition from Edwards Lifesciences.Evercore ISI lowered its price target to $120 from $134, saying organic growth came in “a tad below” expectations and base organic guidance was effectively reduced by about 50 basis points.However, Abbott said that the $23 billion acquisition of Exact Sciences is expected to contribute about $3 billion in incremental sales this year and support longer-term growth as Abbott continues to shift away from declining COVID testing revenue.<h2 class="st-heading-2">ASBP Slumps On Dilution Concerns</h2>ASBP shares remained under pressure after stockholders approved several proposals expanding the company’s flexibility to issue additional equity and restructure its capital base.At a special meeting earlier this month, investors approved a reverse stock split within a range of 1-for-5 to 1-for-500 and authorized the issuance of conversion shares tied to Series A preferred stock. Stockholders also approved additional equity issuance under an existing purchase agreement with Arena Business Solutions Global SPC II. A proposal to increase the authorized common shares from 490 million to 700 million was also approved.The company separately completed a preferred-stock financing tranche, generating about $10 million in proceeds, while converting part of its outstanding debt into equity, underscoring investor concerns around dilution risk and huge funding needs.Additionally, Aspire entered a letter of intent to acquire Dura Driver Control Systems in a $30 million deal to expand its footprint beyond drug delivery.<h2 class="st-heading-2">How Do Retail Traders Feel About LCID, ABT, ASBP?</h2>On Stocktwits, retail sentiment for LCID and ABT was ‘extremely bullish’ amid ‘extremely high’ message volume, while sentiment for ASBP was ‘bullish’ with ‘extremely high’ message volume.Over the past year, LCID shares have declined 67%, ABT is down 25%, and ASBP has plunged 99%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-outpaces-2025-gains-battery-swap-rollout-focus/cZJUf82RIx7">Nio Stock Already Outruns Last Year’s Gains — Now A Massive Battery-Swap Push Is Coming Into Spotlight</a>

In this photo illustration, the logo of Lucid Group, Inc. is displayed on a smartphone screen, with a stock market chart in the background, on May 4, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

LCID, ABT, ASBP Stocks Hit 52-Week Lows Today: What’s Driving The Selloff?

LCID and ABT each fell about 6% on Thursday, while ASBP plunged 45%, bucking a broader market rally.

<ul class="summary-bullets"><li>Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial.</li><li>The firm said OTASA demonstrated faster and higher absorption of acetylsalicylic acid compared with chewed aspirin tablets.</li><li>The company said that&nbsp;&nbsp;Early safety evaluations showed the product was well tolerated, with no adverse events reported.</li></ul>Shares of Aspire Biopharma Holdings (ASBP) shot up 32% on Wednesday after the company said it received favorable feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-investigational new drug (IND) meeting for OTASA, its high-dose sublingual (under-the-tongue) aspirin aimed at emergency treatment of suspected heart attacks.The FDA’s feedback supports a planned Section 505(b)(2) New Drug Application (NDA) submission in the second half of 2026, the company added.Based on the agency’s guidance, Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial. The study will enroll 32 healthy volunteers and compare OTASA 162 mg with the current standard of care, two chewed 81 mg aspirin tablets, by measuring inhibition of serum thromboxane B2, a marker linked to blood clotting.The pre-IND submission was supported by encouraging pilot clinical data. Aspire said OTASA demonstrated faster and higher absorption of acetylsalicylic acid compared with chewed aspirin tablets. The sublingual formulation also achieved rapid platelet inhibition, reducing thromboxane B2 levels within the first two minutes after administration. Early safety evaluations showed the product was well tolerated, with no adverse events reported.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/ASBP">ASBP</a> remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/ASBP_jpg_d2fe432dd1.webp" alt="ASBP.jpg" width="906" height="105"><figcaption>&nbsp;</figcaption></figure>Users speculated that the company could already be engaged in licensing negotiations.<stembedurl>https://stocktwits.com/juned/message/641088627</stembedurl><stembedurl>https://stocktwits.com/Pennystockmadness/message/641086670</stembedurl><h2 class="st-heading-2">Stock Price</h2>The update and the subsequent rally in stock price come at a time when the company has been dealing with listing concerns stemming from its low share price. In November, investors approved a proposal allowing the board to implement a reverse stock split at a ratio of 1-for-5 to 1-for-40, within one year if needed.The company has also secured Nasdaq approval to remain listed, contingent on meeting minimum bid price and equity requirements by late January and mid-February 2026.At present, the stock is trading near the $0.14 mark.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/silver-falls-ahead-of-index-fund-rebalancing/cmxz3OLR420">Silver Tumbles 5% Amid Profit-Booking And&nbsp;Scheduled Reshuffling Of Commodity Index Funds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin –  Retail Expects Licensing Negotiations Soon

The FDA’s feedback supports a planned new drug application submission in the second half of 2026.

Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company was founded on February 2, 2025 and is headquartered in Estero, FL.

Aspire Biopharma Holdings Inc.

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Current Price	$0.185
Prev Close	$0.155
Open	$0.1214
Dividend Yield	0.00%
50-Day Moving Average	$0.775
Beta	1.46
Avg. Volume	28.29M
PE Ratio	-0.01

52-Week High	$35.01
52-Week Low	$0.1103
Market Capitalization	$929,463.00
EPS (Annual)	-$16.38
Price to Book	-0.10
Revenue Per Employee	N/A

ASBP
Aspire Biopharma Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ASBP News

ASBPAspire Biopharma Holdings Inc